The FDA Orders Pfizer Inc. (NYSE: PFE) to Test Another Round of Paxlovid on Rebound Patients

The U.S Food and Drug Administration has requested Pfizer Inc. (NYSE: PFE) to test another round of Paxlovid on patients experiencing rebound COVID-19 after treatment. The regulator also asked Pfizer to produce the first results from a randomisPFEed controlled trial that evaluated the effects of a second oral drug dose. The regulator expects these results by September 30.

The order comes after an increased number of cases where patients have recurring symptoms or viral infection after treatment with Paxlovid. While the company claims that the cases are rare, the FDA has started talks with Pfizer over the matter.

The FDA has stated the need for a protocol to treat people with recurring infection

It is now working with Pfizer to come up with appropriate measures.

Famous cases of rebound infection

The most famous case of a rebound infection was with U.S President Joe Biden. The President experienced symptoms days after he was treated with Paxlovid. Biden tested positive for seven straight days after his rebound diagnosis.

Biden had initially tested positive on July 21. He was treated and then tested negative twice after his isolation. Days later, the president tested positive again and developed symptoms of COVID-19, including a cough.

Another famous case for rebound COVID was with Dr Anthony Fauci, Biden’s Chief Medical Adviser. Dr Fauci reports that he experienced worse symptoms after he received treatment due to his first round of infection. Fauci, who is 81 l, received Paxlovid as his age put him at risk for severe disease. He states that the drug served this purpose and protected him from severe illness.

The CDC gives guidelines for rebound illness

The Centre for Disease Control and Prevention advises people with rebound disease after taking Paxlovid to isolate and keep wearing masks for ten days from the reappearance of symptoms. While many still test positive after ten days, they are less likely to shed the virus.

Although many people believe the rebound disease only occurs in people who takes Paxlovid, a new study indicates that anyone could experience it. The study indicates that 27% of untreated people experience rebound symptoms a month after the initial infection. However, this research isn’t peer reviewed.

 

For consideration of being featured on WallstreetPR, contact editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.